Generic Name and Formulations:
Rotigotine 1mg/24hours, 2mg/24hours, 3mg/24hours, 4mg/24hours, 6mg/24hours, 8mg/24hours; transdermal patch; contains sulfite.
Company:
UCB Inc.
Idiopathic Parkinson's disease.
Apply to clean, dry, intact skin on abdomen, thigh, hip, flank, shoulder, or upper arm. Early-stage: initially 2mg/24hrs patch once daily; may increase weekly by 2mg/24hrs if needed; max 6mg/24hrs once daily. Advanced-stage: initially 4mg/24hrs patch once daily; may increase weekly by 2mg/24hrs if needed; max 8mg/24hrs once daily. Rotate application site (allow 14 days before reapplying to same site). Shave site at least 3 days before application if hairy. Avoid abrupt cessation; reduce by 2mg/24hrs every other day.
Not established.
Dopamine agonist (non-ergot).
Avoid external heat sources. Remove patch before cardioversion, MRI. Sleep disorders; consider discontinuing if excessive daytime sleepiness or falling asleep during activities occurs. Psychotic disorder. Increased risk of symptomatic hypotension; monitor BP esp. during dose adjustments. Cardiovascular disease. Conditions aggravated by fluid retention (eg, CHF, renal insufficiency). Asthma. Pre-existing dyskinesia. Severe hepatic impairment. Monitor for melanoma. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with concomitant alcohol, sedating drugs or other CNS depressants (eg, benzodiazepines, antipsychotics, antidepressants). May be antagonized by metoclopramide, antipsychotics.
Nausea, vomiting, somnolence (may be sudden), application site reactions, dizziness, anorexia, hyperhidrosis, insomnia, peripheral edema, dyskinesia; orthostatic hypotension, syncope, hallucinations, psychotic-like behavior, intense urges/compulsions, hypertension, heart rate elevation.
Hepatic.
Renal, fecal.
NO
Patches—30
Restless legs syndrome (RLS).
Apply to clean, dry, intact skin on abdomen, thigh, hip, flank, shoulder, or upper arm. Initially 1mg/24hrs patch once daily; may increase weekly by 1mg/24hrs if needed; max 3mg/24hrs once daily. Rotate application site (allow 14 days before reapplying to same site). Shave site at least 3 days before application if hairy. Avoid abrupt cessation; reduce by 1mg/24hrs every other day.
Not established.
Dopamine agonist (non-ergot).
Avoid external heat sources. Remove patch before cardioversion, MRI. Sleep disorders; consider discontinuing if excessive daytime sleepiness or falling asleep during activities occurs. Psychotic disorder. Increased risk of symptomatic hypotension; monitor BP esp. during dose adjustments. Cardiovascular disease. Conditions aggravated by fluid retention (eg, CHF, renal insufficiency). Asthma. Pre-existing dyskinesia. Severe hepatic impairment. Monitor for melanoma. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with concomitant alcohol, sedating drugs or other CNS depressants (eg, benzodiazepines, antipsychotics, antidepressants). May be antagonized by metoclopramide, antipsychotics.
Nausea, vomiting, somnolence (may be sudden), application site reactions, headache, dizziness, anorexia, hyperhidrosis, insomnia, peripheral edema, dyskinesia; orthostatic hypotension, syncope, hallucinations, psychotic-like behavior, intense urges/compulsions, hypertension, heart rate elevation, augmentation/rebound of RLS symptoms.
Hepatic.
Renal, fecal.
NO
Patches—30